Needham analyst Serge Belanger maintained a Buy rating on Heron Therapeutics (NASDAQ:HRTX) on Thursday, setting a price target of $28, which is approximately 65.68% above the present share price of $16.9.
Belanger expects Heron Therapeutics to post earnings per share (EPS) of -$0.57 for the third quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Heron Therapeutics, with an average price target of $31.33.
The analysts price targets range from a high of $70 to a low of $19.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $25.4 million and a net profit of -$52.73 million. The company's market cap is $1.58 billion.
According to TipRanks.com, Needham analyst Serge Belanger is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 2.6% and a 40.91% success rate.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood (NYSE:RWT) City, CA.